Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • December 2008 (Revised October 2013)
  • Case
  • HBS Case Collection

Amylin Pharmaceuticals: Diabetes and Beyond (A)

By: Richard G. Hamermesh and Rachel Gordon
  • Format:Print
  • | Language:English
  • | Pages:19
ShareBar

Abstract

Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time, the company has a second drug, Byetta, in its pipeline. Graham must decide how to manage the company's limited resources while also finalizing another deal that has huge future potential. Graham knows that Amylin's immediate success depends on its ability to commercialize its products, but its long-term success depends on replenishing its pipeline. Can the company do it all successfully?

Keywords

Regulations; Drug Regulations; Symlin; Negotiation; Governing Rules, Regulations, and Reforms; Resource Allocation; Negotiation Deal; Product Development; Research and Development; Commercialization; Pharmaceutical Industry; United States

Citation

Hamermesh, Richard G., and Rachel Gordon. "Amylin Pharmaceuticals: Diabetes and Beyond (A)." Harvard Business School Case 809-011, December 2008. (Revised October 2013.)
  • Educators
  • Purchase

About The Author

Richard G. Hamermesh

→More Publications

Related Work

    • April 2009
    • Faculty Research

    Amylin Pharmaceuticals: Diabetes and Beyond (TN)

    By: Richard G. Hamermesh and Rachel Gordon
    • November 2012
    • Faculty Research

    Amylin Pharmaceuticals (B)

    By: Richard G. Hamermesh and Carin-Isabel Knoop
    • December 2008 (Revised October 2013)
    • Faculty Research

    Amylin Pharmaceuticals: Diabetes and Beyond (A)

    By: Richard G. Hamermesh and Rachel Gordon
Related Work
  • Amylin Pharmaceuticals: Diabetes and Beyond (TN) By: Richard G. Hamermesh and Rachel Gordon
  • Amylin Pharmaceuticals (B) By: Richard G. Hamermesh and Carin-Isabel Knoop
  • Amylin Pharmaceuticals: Diabetes and Beyond (A) By: Richard G. Hamermesh and Rachel Gordon
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College